

(b)(3) =




## DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

## PUBLIC HEALTH SERVICE

19 October 1960

National Institute of Mental Health Addiction Research Center U.S. Public Health Service Hospital Lexington, Kentucky



In accordance with Ray's telephone call of October 19th I have the following supplies of the materials on hand:

Agroclavine (V-A-18), 440 mg,

Dihydroagroclavine (V-A-19), 450 mg,

Dihydroergokryptine (V-A-20), 25 mg,

7,9-Dimethyl-9-hydroxy-4,5,5a,6,6a,7,8,9-octahydroindolo [4.3-fg] quinoline (V-A-21, or Lilly 23194), 315 mg,

Elymoclavine (V-A-22), 100 mg.

You may have any or all of these materials since, with the exception of V-A-21, I can get additional supplies from Dr. T. Yui of Takeda, Japan.

We have never studied V-A-20 here. It was sent, without our requesting it, in the hope we would test if for adrenergic blocking properties.

Key reference on numbers V-A-18, 19, 21 and 22 is: Yui, T. and Takeo, Y.: Neuropharmacological studies on a new series of ergot alkaloids, Japanese Journal of Pharmacology, 7: 157-161 (March) 1958. The only information I have on V-A-21 or Lilly 23194 is in the form of thermofax sheets sent me by Dr. Slater of the Lilly Laboratories.

They indicate LSD-like effects in cats and rats, but in man this compound had potent hypnotic properties.

Looking forward to seeing you soon,

Very sincerely,

Harris Isbell, M. D. Director

HI:bws